{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:11:01Z","timestamp":1779102661759,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109089","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:15:57Z","timestamp":1779099357000},"source":"Crossref","is-referenced-by-count":0,"title":["Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review"],"prefix":"10.7759","author":[{"given":"Amir","family":"Meftah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolaji","family":"Yoade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cade","family":"Cowart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olufemi","family":"Popoola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olorunfemi","family":"Afe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Efremoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chino","family":"Ezema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bamidele","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolu","family":"Olupona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Zyprexa (Olanzapine)","author":"Eli Lilly and Company","year":"2026","unstructured":"Eli Lilly and Company. Zyprexa (Olanzapine). Eli Lilly and Company, Indianapolis, IN; 2026."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v61n0907","article-title":"A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder","volume":"61","author":"Guille C","year":"2000","unstructured":"Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000, 61:638-42. 10.4088\/jcp.v61n0907","journal-title":"J Clin Psychiatry"},{"key":"ref3","article-title":"Clozaril (Clozapine) [Prescribing Information]","author":"Novartis Pharmaceuticals Corporation","year":"2020","unstructured":"Novartis Pharmaceuticals Corporation. Clozaril (Clozapine) [Prescribing Information]. Novartis Pharmaceuticals Corporation, Rosemont, PA; 2020."},{"key":"ref4","unstructured":"HLS Therapeutics (USA), Inc. Clozaril (Clozapine) [prescribing information] (2020). (2026). Accessed. February 17, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/019758s095lbl.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi M","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, et al.. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017, 13:757-77. 10.2147\/TCRM.S117321","journal-title":"Ther Clin Risk Manag"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger T","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al.. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020, 7:64-77. 10.1016\/S2215-0366(19)30416-X","journal-title":"Lancet Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"DE Hert M","year":"2009","unstructured":"DE Hert M, Schreurs V, Vancampfort D, VA Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009, 8:15-22. 10.1002\/j.2051-5545.2009.tb00199.x","journal-title":"World Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19:1-93. 10.2165\/00023210-200519001-00001","journal-title":"CNS Drugs"},{"key":"ref9","article-title":"Hyperglycemia and antipsychotic medications","volume":"62","author":"Haupt DW","year":"2001","unstructured":"Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001, 62:15-41.","journal-title":"J Clin Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds GP","year":"2010","unstructured":"Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2010, 125:169-79. 10.1016\/j.pharmthera.2009.10.010","journal-title":"Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker DJ","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024, 47:1873-88. 10.2337\/dci24-0003","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i21.7495","article-title":"Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: a case report","volume":"10","author":"Zhang L","year":"2022","unstructured":"Zhang L, Yu WJ, Zhu H, Li HF, Qiao J. Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: a case report. World J Clin Cases. 2022, 10:7495-501. 10.12998\/wjcc.v10.i21.7495","journal-title":"World J Clin Cases"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442551","article-title":"The history of clozapine","volume":"99","author":"Hippius H","year":"1989","unstructured":"Hippius H. The history of clozapine. Psychopharmacology (Berl). 1989, 99:S3-5. 10.1007\/BF00442551","journal-title":"Psychopharmacology (Berl)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(99)00059-1","article-title":"Pharmacologic treatment of schizophrenia","volume":"15","author":"Kane JM","year":"1999","unstructured":"Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999, 15:1396-408. 10.1016\/s0006-3223(99)00059-1","journal-title":"Biol Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer HY","year":"2012","unstructured":"Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012, 6:134-44.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia","volume":"99","author":"Meltzer HY","year":"1989","unstructured":"Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989, 99:S18-27. 10.1007\/BF00442554","journal-title":"Psychopharmacology (Berl)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer HY","year":"2011","unstructured":"Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011, 11:59-67. 10.1016\/j.coph.2011.02.007","journal-title":"Curr Opin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin K","year":"1996","unstructured":"Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996, 169:483-8. 10.1192\/bjp.169.4.483","journal-title":"Br J Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane J","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988, 45:789-96. 10.1001\/archpsyc.1988.01800330013001","journal-title":"Arch Gen Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2016.14.4.323","article-title":"Clozapine monitoring in clinical practice: beyond the mandatory requirement","volume":"14","author":"Kar N","year":"2016","unstructured":"Kar N, Barreto S, Chandavarkar R. Clozapine monitoring in clinical practice: beyond the mandatory requirement. Clin Psychopharmacol Neurosci. 2016, 14:323-9. 10.9758\/cpn.2016.14.4.323","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer HY","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, et al.. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003, 60:82-91. 10.1001\/archpsyc.60.1.82","journal-title":"Arch Gen Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia","volume":"119","author":"Meyer JM","year":"2009","unstructured":"Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009, 119:4-14. 10.1111\/j.1600-0447.2008.01317.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12416","article-title":"Clozapine-induced myocarditis, a widely overlooked adverse reaction","volume":"132","author":"Ronaldson KJ","year":"2015","unstructured":"Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015, 132:231-40. 10.1111\/acps.12416","journal-title":"Acta Psychiatr Scand"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"Stroup TS","year":"2014","unstructured":"Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014, 65:186-92. 10.1176\/appi.ps.201300180","journal-title":"Psychiatr Serv"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133x(95)00069-p","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley CM","year":"1996","unstructured":"Beasley CM, Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996, 14:111-23. 10.1016\/0893-133x(95)00069-p","journal-title":"Neuropsychopharmacology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133x(94)00129-n","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster FP","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, et al.. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996, 14:87-96. 10.1016\/0893-133x(94)00129-n","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran PV","year":"1997","unstructured":"Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997, 17:407-18. 10.1097\/00004714-199710000-00010","journal-title":"J Clin Psychopharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman JA","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al.. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353:1209-23. 10.1056\/NEJMoa051688","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen M","year":"1999","unstructured":"Tohen M, Sanger TM, McElroy SL, et al.. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999, 156:702-9. 10.1176\/ajp.156.5.702","journal-title":"Am J Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","volume":"51","author":"Newcomer JW","year":"2006","unstructured":"Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006, 51:480-91. 10.1177\/070674370605100803","journal-title":"Can J Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers GA","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al.. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020, 177:868-72. 10.1176\/appi.ajp.2020.177901","journal-title":"Am J Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"14","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al.. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013, 14:951-62. 10.1016\/s0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur S","year":"2001","unstructured":"Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001, 158:360-9. 10.1176\/appi.ajp.158.3.360","journal-title":"Am J Psychiatry"},{"key":"ref36","unstructured":"US Food and Drug Administration. FDA removes Risk Evaluation and Mitigation Strategy (REMS) program for the antipsychotic drug clozapine. neutropenia risk remains, but REMS no longer necessary and REMS may prevent treatment access. FDA Drug Safety Communication. (2025). Accessed: April 25, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-removes-risk-evaluation-and-mitigation-strategy-rems-progr...."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto S","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005, 10:79-104. 10.1038\/sj.mp.4001556","journal-title":"Mol Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week Phase 3 study","volume":"177","author":"Correll CU","year":"2020","unstructured":"Correll CU, Newcomer JW, Silverman B, et al.. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week Phase 3 study. Am J Psychiatry. 2020, 177:1168-78. 10.1176\/appi.ajp.2020.19121279","journal-title":"Am J Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker DJ","year":"2017","unstructured":"Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017, 127:4217-27. 10.1172\/JCI97233","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov S","year":"1987","unstructured":"Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987, 79:616-9. 10.1172\/JCI112855","journal-title":"J Clin Invest"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.6.0385","article-title":"The glucagon-like peptides","volume":"20","author":"Kieffer TJ","year":"1999","unstructured":"Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999, 20:876-913. 10.1210\/edrv.20.6.0385","journal-title":"Endocr Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.80.3.7883856","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon CF","year":"1995","unstructured":"Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995, 80:952-7. 10.1210\/jcem.80.3.7883856","journal-title":"J Clin Endocrinol Metab"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker DJ","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006, 3:153-65. 10.1016\/j.cmet.2006.01.004","journal-title":"Cell Metab"},{"key":"ref44","unstructured":"Byetta injection 250 mcg\/ml. (2005). Accessed. February 17, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_Byetta_approv.PDF."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"15","author":"Eng J","year":"1992","unstructured":"Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992, 15:7402-5. 10.1016\/S0021-9258(18)42531-8","journal-title":"J Biol Chem"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre M","year":"2009","unstructured":"Marre M, Shaw J, Br\u00e4ndle M, et al.. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009, 26:268-78. 10.1111\/j.1464-5491.2009.02666.x","journal-title":"Diabet Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"7","author":"Astrup A","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, et al.. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009, 7:1606-16. 10.1016\/s0140-6736(09)61375-1","journal-title":"Lancet"},{"key":"ref50","unstructured":"Center for Drug Evaluation and Research. (2014). Accessed. February 22, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206321Orig1s000Approv.pdf.."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"13","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019, 13:121-30. 10.1016\/s0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series","volume":"13","author":"Prasad F","year":"2023","unstructured":"Prasad F, De R, Korann V, et al.. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. Ther Adv Psychopharmacol. 2023, 13:20451253231165169. 10.1177\/20451253231165169","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff AL","year":"2012","unstructured":"Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012, 153:647-58. 10.1210\/en.2011-1443","journal-title":"Endocrinology"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study","volume":"157","author":"Henderson DC","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000, 157:975-81. 10.1176\/appi.ajp.157.6.975","journal-title":"Am J Psychiatry"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0481-5","article-title":"Clozapine and gastrointestinal hypomotility","volume":"31","author":"Cohen D","year":"2017","unstructured":"Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs. 2017, 31:1083-91. 10.1007\/s40263-017-0481-5","journal-title":"CNS Drugs"},{"key":"ref57","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13050127","article-title":"A closer look at the dermatological profile of GLP-1 agonists","volume":"13","author":"Persson C","year":"2025","unstructured":"Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025, 13:127.","journal-title":"Diseases"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s0278-5846(01)00258-5","article-title":"Olanzapine-induced agranulocytosis: a case report and review of the literature","volume":"26","author":"Tolosa-Vilella C","year":"2002","unstructured":"Tolosa-Vilella C, Ruiz-Ripoll A, Mari-Alfonso B, Naval-Sendra E. Olanzapine-induced agranulocytosis: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2002, 26:411-4. 10.1016\/s0278-5846(01)00258-5","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir JM","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993, 329:162-7. 10.1056\/NEJM199307153290303","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski PK","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024, 13:10.3390\/jcm13216292","journal-title":"J Clin Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases","volume":"69","author":"Palmer SE","year":"2008","unstructured":"Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008, 69:759-68. 10.4088\/jcp.v69n0509","journal-title":"J Clin Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse JB","year":"2004","unstructured":"Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004, 27:2628-35. 10.2337\/diacare.27.11.2628","journal-title":"Diabetes Care"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_405_16","article-title":"Seizure associated with olanzapine","volume":"7","author":"Uvais NA","year":"2018","unstructured":"Uvais NA, Sreeraj VS. Seizure associated with olanzapine. J Family Med Prim Care. 2018, 7:1090-2. 10.4103\/jfmpc.jfmpc_405_16","journal-title":"J Family Med Prim Care"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.41.3.369","article-title":"Clozapine-related seizures","volume":"41","author":"Devinsky O","year":"1991","unstructured":"Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991, 41:369-71. 10.1212\/wnl.41.3.369","journal-title":"Neurology"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan EP","year":"2004","unstructured":"Harrigan EP, Miceli JJ, Anziano R, et al.. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004, 24:62-9. 10.1097\/01.jcp.0000104913.75206.62","journal-title":"J Clin Psychopharmacol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2006.2.4.583","article-title":"Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics","volume":"2","author":"Nagamine T","year":"2006","unstructured":"Nagamine T. Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics. Neuropsychiatr Dis Treat. 2006, 2:583-5. 10.2147\/nedt.2006.2.4.583","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.162","article-title":"Recurrent reactive hypoglycemia due to clozapine-induced glucose intolerance: a case report","volume":"2","author":"Kawai F","year":"2023","unstructured":"Kawai F, Watanabe S, Ebihara H, et al.. Recurrent reactive hypoglycemia due to clozapine-induced glucose intolerance: a case report. PCN Rep. 2023, 2:e162. 10.1002\/pcn5.162","journal-title":"PCN Rep"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2009.05.1997","article-title":"Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits","volume":"121","author":"Nauck M","year":"2009","unstructured":"Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med. 2009, 121:5-15. 10.3810\/pgm.2009.05.1997","journal-title":"Postgrad Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221079971","article-title":"Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis","volume":"12","author":"He Y","year":"2022","unstructured":"He Y, Fang W, Li Z, et al.. Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis. Ther Adv Psychopharmacol. 2022, 12:20451253221079971. 10.1177\/20451253221079971","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00413-6","article-title":"Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report","volume":"21","author":"Rodriguez V","year":"2020","unstructured":"Rodriguez V, Hanley K, Arias AJ, Quattrone D, Kuforiji J, Whiskey E, Shergill SS. Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report. BMC Pharmacol Toxicol. 2020, 21:35. 10.1186\/s40360-020-00413-6","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials","volume":"103","author":"Monami M","year":"2014","unstructured":"Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. 2014, 103:269-75. 10.1016\/j.diabres.2014.01.010","journal-title":"Diabetes Res Clin Pract"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113830","article-title":"Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients","volume":"299","author":"Lee SE","year":"2021","unstructured":"Lee SE, Lee NY, Kim SH, Kim KA, Kim YS. Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients. Psychiatry Res. 2021, 299:113830. 10.1016\/j.psychres.2021.113830","journal-title":"Psychiatry Res"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind DJ","year":"2018","unstructured":"Siskind DJ, Russell AW, Gamble C, et al.. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab. 2018, 20:1050-5. 10.1111\/dom.13167","journal-title":"Diabetes Obes Metab"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12101344","article-title":"Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes","volume":"170","author":"Ish\u00f8y PL","year":"2013","unstructured":"Ish\u00f8y PL, Knop FK, Vilsb\u00f8ll T, Glenth\u00f8j BY, Ebdrup BH. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry. 2013, 170:681-2. 10.1176\/appi.ajp.2013.12101344","journal-title":"Am J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471233-potential-of-glucagon-like-peptide-1-glp-1-receptor-agonists-in-mitigating-metabolic-side-effects-associated-with-clozapine-or-olanzapine-therapy-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:16:05Z","timestamp":1779099365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471233-potential-of-glucagon-like-peptide-1-glp-1-receptor-agonists-in-mitigating-metabolic-side-effects-associated-with-clozapine-or-olanzapine-therapy-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":74,"URL":"https:\/\/doi.org\/10.7759\/cureus.109089","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}